New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
09:59 EDTPAY, KMB, DTV, THR, GNW, MIND, ESV, ARCP, CTL, MO, DB, AZN, ATK, CHAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ATK (ATK) downgraded to Neutral from Buy at Goldman... Altria Group (MO) downgraded to Market Perform from Outperform at Wells Fargo... American Realty (ARCP) downgraded to Neutral from Outperform at RW Baird... AstraZeneca (AZN) downgraded to Market Perform from Outperform at Leerink... CenturyLink (CTL) downgraded to Equal Weight from Overweight at Morgan Stanley... China Telecom (CHA) downgraded to Neutral from Buy at Goldman... Deutsche Bank (DB) downgraded to Underperform from Neutral at BofA/Merrill... DirecTV (DTV) downgraded to Hold from Buy at Wunderlich... Ensco (ESV) downgraded to Hold from Buy at Jefferies... Genworth (GNW) downgraded to Underweight from Equal Weight at Morgan Stanley... Kimberly Clark (KMB) downgraded to Hold from Buy at Argus... Mitcham Industries (MIND) downgraded to Accumulate from Buy at Global Hunter... Thermon Group (THR) downgraded to Hold from Buy at KeyBanc... VeriFone (PAY) downgraded to Neutral from Positive at Susquehanna.
News For ATK;MO;ARCP;AZN;CTL;CHA;DB;DTV;ESV;GNW;KMB;MIND;THR;PAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 23, 2015
10:14 EDTKMBKimberly-Clark raises FY15 FORCE cost savings to $350M from $305M
Reports savings from 2014 organization restructuring of $20M. Sees FY15 input cost deflation of $100M-$200M. The company said currency drag is expected to have a negative impact on FY15 EPS by more than 20%. The drag on Q2 EPS was approximately 30c per share. Comments taken from Q2 earnings conference call.
07:42 EDTKMBKimberly-Clark reports Q2 Personal Care sales down 6% to $2.3B
Subscribe for More Information
07:41 EDTKMBKimberly-Clark reports Q2 organic sales up 4%
Reports Q2 organic sales up 10% in developing and emerging markets.
07:37 EDTKMBKimberly-Clark says restructuring expected to be completed by end of 2016
Subscribe for More Information
07:36 EDTKMBKimberly-Clark raises FY15 adjusted EPS to $5.65-$5.80 from $5.60-$5.80
Subscribe for More Information
07:35 EDTKMBKimberly-Clark reports Q2 adjusted EPS $1.41, consensus $1.36
Subscribe for More Information
July 22, 2015
13:58 EDTAZNPiper cuts Array target by only 50c after failed trial
Piper Jaffray analyst Edward Tenthoff says selumetinib for Uveal Melanoma is a small indication and represented only a small part of his valuation for Array BioPharma (ARRY). As such, after partner AstraZeneca (AZN) announced that selumetinib failed in the Phase III trial, the analyst cut his price target for Array by only 50c to $14.50. The primary drivers for Array remain binimetinib and encorafenib in NRAS and BRAF melanoma and low-grade serous ovarian cancer, the analyst tells investors in a research note. He keeps an Overweight rating on the stock.
09:07 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTCTLCenturyLink expands global data center presence in 1H15
Subscribe for More Information
05:21 EDTGNWGenworth enters into talks with AXA to sell lifestyle protection business
Genworth Financial (GNW) announces it has entered into exclusive negotiations with AXA S.A. (AXAHY) after receiving an irrevocable offer to purchase its lifestyle protection insurance business. The company expects to accept the offer and execute an associated purchase agreement upon completion of the French works council consultation process. The sale price is expected to be approximately $510M and the company will record an after-tax loss of approximately $310M in Q2 related to the expected sale and pension settlement costs. Net proceeds from the transaction, net of pension settlement costs and transaction related expenses, are estimated to be approximately $400M. Genworth plans to use these proceeds to advance compliance with the Private Mortgage Insurer Eligibility Requirements and to reduce debt levels. The sale is expected to close by the end of 2015 and is subject to other customary conditions, including requisite regulatory approvals.
05:12 EDTAZNAstraZeneca says Phase 3 study of selumetinib did not meet primary endpoint
AstraZeneca (AZN) announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing. Selumetinib is a MEK inhibitor in late-stage development, with a primary Phase 3 program in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase 3 study in differentiated thyroid cancer and in a Phase 2 registration study in patients with neurofibromatosis Type 1. Selumetinib is an oral small molecule MEK inhibitor invented by Array BioPharma (ARRY) and licensed to AstraZeneca in 2003.
July 21, 2015
19:34 EDTDTVAT&T pleased with FCC order, sees closing DirecTV deal 'shortly' after approval
Subscribe for More Information
18:54 EDTDTVAT&T announces Department of Justice completed review of acquisition of DirecTV
AT&T (T) released the following statement "We are pleased the Department of Justice has completed its review of our acquisition of DIRECTV (DTV). We look forward to gaining the approval of the Federal Communications Commission so we can quickly begin providing consumers with the benefits of this combination."
18:33 EDTDTVFCC chairman proposes to approve AT&T-DirecTV deal with conditions
In light of news reports concerning the proposed AT&T (T) and DirecTV (DTV) transaction, FCC chairman Tom Wheeler issued the following statement: "An order recommending that the AT&T-DirecTV transaction be approved with conditions has circulated to the commissioners... If the conditions are approved by my colleagues, 12.5M customer locations will have access to a competitive high-speed fiber connection. This additional build-out is about 10 times the size of AT&Tís current fiber-to-the-premise deployment... and more than triples the number of metropolitan areas AT&T has announced plans to serve. In addition, the conditions will build on the 'Open Internet Order' already in effect... First, in order to prevent discrimination against online video competition, AT&T will not be permitted to exclude affiliated video services and content from data caps on its fixed broadband connections. Second, in order to bring greater transparency to interconnection practices, the company will be required to submit all completed interconnection agreements to the Commission, along with regular reports on network performance... We will require an independent officer to help ensure compliance with these and other proposed conditions." Reference Link
18:24 EDTDTVFCC poised to approve AT&T acquisition of DirecTV, WSJ reports
Subscribe for More Information
16:57 EDTDTVFCC poised to approve AT&T acquisition of DirecTV, DJ says
Subscribe for More Information
10:01 EDTKMBOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 20, 2015
16:46 EDTKMBKimberly-Clark initiated with a Neutral at Sterne Agee CRT
Subscribe for More Information
July 17, 2015
14:00 EDTDBEarnings Watch: Morgan Stanley rounds out quarterly results for financial firms
Subscribe for More Information
06:36 EDTDBBaFin accuses Deutsche Bank execs of Libor negligence, WSJ reports
German regulators have accused several Deutsche Bank executives of failing to halt or notify regulators about years of attempted market manipulation, the Wall Street Journal reports, according to a confidential report. BaFin, Germany's financial watchdog, sent the report to Deutsche Bank's board on May 11, less than a month before the bank announced that its co-CEOs Anshu Jain and Jurgen Fitschen intended to resign, the report says. Jain was singled out particularly int he letter for allegedly providing inadequate leadership and failing to stop manipulation of the London interbank offered rate, or Libor, and other benchmarks, the report says. Four other Deutsche bank board members and two other senior executives were also harshly criticized by BaFin in the report for negligence and selective disclosures, the Wall Street Journal says. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use